SH3PXD2A and cancer: Loss of invadopodia formation in cancer cells by reduction of tyrosine kinase substrate with five SH3 domains (Tks5) abundance, a master regulator of invadopodia, reduced invasive behavior in vitro and tumorigenicity in vivo because cancer cells without invadopodia lack ECM degradative ability [101,102].